• Md Shahidul Islam.
• Department of Clinical Science and Education, Research Center, Karolinska Institutet, Stockholm South General Hospital, 3rd Floor, Södersjukhuset, SE-118 83, Stockholm, Sweden. shahidul.islam@ki.se.
• Adv Exp Med Biol. 2017 Jan 1; 906: 67-74.

AbstractClinicians need to make decisions about the use of thrombolytic (fibrinolytic) therapy for pulmonary embolism (PE) after carefully considering the risks of major complications from bleeding, and the benefits of treatment, for each individual patient. They should probably not use systemic thrombolysis for PE patients with normal blood pressure. Treatment by human recombinant tissue plasminogen activator (rt-PA), alteplase, saves the lives of high-risk PE patients, that is, those with hypotension or in shock. Even in the absence of strong evidence, clinicians need to choose the most appropriate regimen for administering alteplase for individual patients, based on assessment of the urgency of the situation, risks for major complications from bleeding, and patient's body weight. In addition, invasive strategies should be considered when absolute contraindications for thrombolytic therapy exist, serious complications arise, or thrombolytic therapy fails.

24 keywords...

hide…